Clinical trial of new drug candidate to prevent Clostridium difficile infection (CDI)
Clinical trial of new drug candidate to prevent Clostridium difficile infection
Aiming to build on positive pre-clinical results reported from a series of proof-of-concept efficacy studies completed by Dr Melanie Hutton and Professor Dena Lyras at the Monash BDI, Phase 1/2 clinical trials of an oral immunotherapeutic targeting the prevention of CDI will start by the end of Quarter 2 this year. CDI - which results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics- is a major medical problem with a huge economic cost. Read more